Specific immunotherapy is the only causative treatment of type-1 allergy. In the classic, subcutaneous immunotherapy (SCIT) increasing amounts of allergen are injected in the upper arm in a weekly interval in order to “desensitize – make the patient unreactive” to the allergen.  After reaching a platform dose (= maintainence dose), the allergy is given in an interval of 4 to 6 weeks for a period of up to three years. SCIT is the golden standard.

There is also a sublingual route of administering specific immunotherapy: either by drops (SLIT – sublingual immunotherapy) or by tablets put under the tongue (AIT – allergen immunotherapy tablet, at the moment only available for grass pollen). Due to therapeutic efficacy, AIT is preferred.